Last week Llusern Scientific presented a new poster that examined whether Lodestar DX could be used to accurately identify true polymicrobial infections.
The poster was written in conjunction with Norfolk and Norwich University Hospitals and was presented at the British Society for Antimicrobial Chemotherapy Winter Conference held on 4-5 December 2024.
The evaluation looked at 35 heavily contaminated patient samples from 241 selected for analysis and concluded that “in clinical scenarios where the growth is deemed significant, Lodestar DX is able to accurately identify the common uropathogens present.”
Download the poster here: BSAC Poster FINAL 2
The Lodestar DX analyser and testing system is registered with the European Patent Office (European Patent Application no: 22732302.9) and the US Patent and Trademark Office (no.18/558,490).